TY - JOUR
T1 - An integrated quantitative index for measuring chronic multisite pain
T2 - The Multiple Areas of Pain (MAP) study
AU - Wallace, Mark S.
AU - North, James
AU - Grigsby, Eric J.
AU - Kapural, Leonardo
AU - Sanapati, Mahendra R.
AU - Smith, Stephen G.
AU - Willoughby, Channing
AU - McIntyre, Patrick J.
AU - Cohen, Steven P.
AU - Rosenthal, Richard M.
AU - Ahmed, Shaik
AU - Vallejo, Ricardo
AU - Ahadian, Farshad M.
AU - Yearwood, Thomas L.
AU - Burton, Allen W.
AU - Frankoski, Edward J.
AU - Shetake, Jai
AU - Lin, Sherry
AU - Hershey, Brad
AU - Rogers, Benjamin
AU - Mekel-Bobrov, Nitzan
N1 - Funding Information:
Funding sources: This project was supported by Boston Scientific, Valencia CA.
Funding Information:
Disclosure and conflicts of interest: Consultant: Boston Scientific. DSMB: Accelerate Trial, St. Jude Medical. Advisory board for Medtronic and Halyard. Consultant for Boston Scientific. Research grants from Nevro. Active clinical research with Medtronic, Nevro, and Halyard.
Publisher Copyright:
© 2018 American Academy of Pain Medicine. All rights reserved.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objective. Despite the high prevalence of chronic multisite pain, there is little consensus on methods to characterize it. Commonly used assessments report only one dimension of pain, that is, intensity, thus ignoring the spatial aspect of pain. We developed a novel pain quantification index, the Integrated Pain Quantification Index (IPQI), on a scale of 0 to 1 that integrates multiple distinct pain measures into a single value, thus representing multidimensional pain information with a single value. Design. Single-visit, noninterventional, epidemiological study. Setting. Fourteen outpatient multidisciplinary pain management programs. Patients. Patients with chronic pain of the trunk and/ or limbs for at least six months with average overall pain intensity of at least 5 on the numeric rating scale. Methods. Development of IPQI was performed in a large population (N 5 810) of chronic pain patients from the Multiple Areas of Pain (MAP) study. Results. Prevalence of two or more noncontiguous painful areas was at 88.3% (95% confidence interval [CI] 5 0.86-0.90), with a mean of 6.3 areas (SD 5 5.57 areas). Prevalence of more than 10% body area in pain was at 52.8% (95% CI 5 0.49-0.56), with a mean at 16.1% (17.16%). On average, IPQI values were near the middle of the scale, with mean and median IPQI at 0.52 (SD 5 0.13) and 0.55, respectively. The IPQI was generalizable and clinically relevant across all domains recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Conclusions. IPQI provided a single pain score for representing complex, multidimensional pain information on one scale and has implications for comparing pain populations across longitudinal clinical trials.
AB - Objective. Despite the high prevalence of chronic multisite pain, there is little consensus on methods to characterize it. Commonly used assessments report only one dimension of pain, that is, intensity, thus ignoring the spatial aspect of pain. We developed a novel pain quantification index, the Integrated Pain Quantification Index (IPQI), on a scale of 0 to 1 that integrates multiple distinct pain measures into a single value, thus representing multidimensional pain information with a single value. Design. Single-visit, noninterventional, epidemiological study. Setting. Fourteen outpatient multidisciplinary pain management programs. Patients. Patients with chronic pain of the trunk and/ or limbs for at least six months with average overall pain intensity of at least 5 on the numeric rating scale. Methods. Development of IPQI was performed in a large population (N 5 810) of chronic pain patients from the Multiple Areas of Pain (MAP) study. Results. Prevalence of two or more noncontiguous painful areas was at 88.3% (95% confidence interval [CI] 5 0.86-0.90), with a mean of 6.3 areas (SD 5 5.57 areas). Prevalence of more than 10% body area in pain was at 52.8% (95% CI 5 0.49-0.56), with a mean at 16.1% (17.16%). On average, IPQI values were near the middle of the scale, with mean and median IPQI at 0.52 (SD 5 0.13) and 0.55, respectively. The IPQI was generalizable and clinically relevant across all domains recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Conclusions. IPQI provided a single pain score for representing complex, multidimensional pain information on one scale and has implications for comparing pain populations across longitudinal clinical trials.
KW - Multisite
KW - Pain
KW - Quantification
UR - http://www.scopus.com/inward/record.url?scp=85055329128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055329128&partnerID=8YFLogxK
U2 - 10.1093/pm/pnx325
DO - 10.1093/pm/pnx325
M3 - Article
C2 - 29474648
AN - SCOPUS:85055329128
SN - 1526-2375
VL - 19
SP - 1425
EP - 1435
JO - Pain Medicine (United States)
JF - Pain Medicine (United States)
IS - 7
ER -